Lancet 383(9911):3139 Tabernero J et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
The overall safety and tolerability profile of orforglipron in ATTAIN-MAINTAIN was consistent with previous orforglipron Phase 3 studies
The excipients, buffers, and preservatives in each pen are identical batch to batch, tested extensively for stability at various temperatures
doi: 10.1172/JCI143777 61 HeM.WeiW.ZhangY.XiangZ.PengD.KasimumaliA.et al
Book Your Consultation Today If youre experiencing symptoms of B12 deficiency or simply want to ensure your levels are optimal, schedule a consultation at KAST Medical Aesthetics in Sandbach, Cheshire
Lee et al